

NEWS RELEASE

FOR IMMEDIATE RELEASE

Wednesday, July 23, 2025



MOUNTAIN VALLEY MD HOLDINGS ANNOUNCES CHANGES TO BOARD OF DIRECTORS

Toronto, Ontario – July 23, 2025 - Mountain Valley MD Holdings Inc. (the “Company” or “MVMD”) (CSE: MVMD) (OTCQB: MVMD) (FRA: 20MP) is pleased to announce the appointment of David Batchelor to its board of directors.

David Batchelor is a seasoned organizational strategist and business transformation expert with more than 25 years of experience advising executive teams and boards on performance improvement, financial discipline, and enterprise value creation. His work spans a wide range of industries—including finance, healthcare, consumer goods, technology, and manufacturing—and includes engagements with global leaders such as Cisco, Coca-Cola, IBM, Merck, Bayer, and Johnson & Johnson. David brings a unique blend of systems thinking, operational insight, and financial acumen to drive results at the intersection of strategy and execution.

With a strong foundation in governance and performance science, David is particularly skilled in helping organizations optimize capital allocation, align leadership structures, and implement high-leverage interventions that improve profitability and accountability. His academic background includes a Master’s degree in Distributed Learning (Organizational Leadership), undergraduate studies in Management Science, and CMA coursework. As a published author and educator, he has held faculty and program leadership roles at the Schulich Executive Education Centre (York University) and Royal Roads University. David is known for his practical, people-centric approach to driving sustainable business success.

“We are very excited to have David Batchelor join our board of directors at this important time in MVMD’s development,” stated Dennis Hancock, President and CEO of MVMD. “David brings a proven track record in business growth, governance, and financial management that aligns perfectly with our priorities for growth, commercialization, and disciplined capital deployment.”

The Company also announces the resignations of Kevin Puloski and Nancy Richardson as directors of the Company.

Mr. Hancock continued: “As we continue to advance our strategic priorities, including commercialization and capital market initiatives, we’re making important enhancements to the composition of our Board. We extend our thanks to the outgoing directors for their contributions and wish them well. The newly appointed director brings relevant perspectives and complementary strengths, reinforcing our commitment to disciplined execution and long-term value creation.”

ABOUT MOUNTAIN VALLEY MD HOLDINGS INC.

Mountain Valley MD is building a world-class organization centered around the implementation, licensing and reselling of key technologies and formulations:

- patented Quicksome™ oral formulation and delivery technologies,
- patented Quicksol™ solubility formulation technology
- licensed product reseller of Agrarius™, a novel agricultural plant signaling technology

Consistent with its vision towards “More Life”, MVMD applies its owned and licensed technologies to its work for advanced delivery of molecules for human and husbandry animal applications, including the development of products for pain management, weight loss, energy, focus, sleep, anxiety, and more. Additionally, MVMD’s work with Agrarius is focused on generating a positive impact on crop yields and reducing fertilizer usage.

MVMD’s patented Quicksome™ technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into highly efficient product formats. The result is a new generation of product formulations that could be capable of delivering nutraceutical and drug molecules into the body faster, with greater impact, efficiency and accuracy.

MVMD’s patented Quicksol™ technology covers all highly solubilized macrocyclic lactones that could be effectively applied in multiple viral applications that could positively impact human and animal health globally.

MVMD’s licensed Agrarius™ agricultural plant signalling technology is designed to be applied to crops to naturally increase yields, reduce fertilizer usage, and increase general resilience to pests and climate change.

For more Company information and contact details, visit www.MVMD.com.

SOURCE: Mountain Valley MD Holdings Inc.

For further information:

Dennis Hancock
President and Chief Executive Officer
Mountain Valley MD Holdings Inc.
Investor Relations @ 647-725-9755
Email: info@mvmd.com
www.MVMD.com

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

Certain statements contained in this news release may constitute forward-looking information. Forward-looking information is often, but not always, identified by the use of words such as "anticipate", "plan", "estimate", "expect", "may", "will", "intend", "should", and similar expressions. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those anticipated in such forward-looking information.

The Company's actual results could differ materially from those anticipated in this forward-looking information as a result of regulatory decisions, competitive factors in the industries in which the Company operates, prevailing economic conditions, and other factors, many of which are beyond the control of the Company.

The Company believes that the expectations reflected in the forward-looking information are reasonable, but no assurance can be given that these expectations will prove to be correct and such forward-looking information should not be unduly relied upon. Any forward-looking information contained in this news release represents the Company's expectations as of the date hereof and is subject to change after such date. The Company disclaims any intention or obligation to update or revise any forward-looking information whether as a result of new information, future events or otherwise, except as required by applicable securities legislation.

Neither the CSE nor OTC has reviewed or approved the contents of this press release.